MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruby, C. E.
Right arrow Articles by Kerkvliet, N. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruby, C. E.
Right arrow Articles by Kerkvliet, N. I.

Vol. 62, Issue 3, 722-728, September 2002

2,3,7,8-Tetrachlorodibenzo-p-dioxin Suppresses Tumor Necrosis Factor-alpha and Anti-CD40-Induced Activation of NF-kappa B/Rel in Dendritic Cells: p50 Homodimer Activation Is Not Affected

Carl E. Ruby, Mark Leid,1 and Nancy I. Kerkvliet

Department of Environmental and Molecular Toxicology, and Environmental Health Science Center, Oregon State University, Corvallis, Oregon

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) suppresses many immune responses, both innate and adaptive. Suppression is mediated by the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor. The AhR mediates TCDD toxicity presumably through the alteration of transcriptional events, either by promoting gene expression or potentially by physically interacting with other transcription factors. Another transcription factor, NF-kappa B/Rel, is involved in several signaling pathways in immune cells and is crucial for generating effective immune responses. Dendritic cells (DCs), considered to be the "pacemakers" of the immune system, were recently recognized as targets of TCDD and are also dependent on NF-kappa B/Rel for activation and survival. In these studies, we investigated whether TCDD would alter the activation of NF-kappa B/Rel in DCs. The dendritic cell line DC2.4 was exposed to TCDD before treatment with tumor necrosis factor alpha  (TNF-alpha ) or anti-CD40, and NF-kappa B/Rel activation was measured by electrophoretic mobility shift assay and immunoblotting. TCDD suppressed the binding of NF-kappa B/Rel to its cognate response element in TNF-alpha - and anti-CD40-treated cells and blocked translocation to the nucleus. The AhR was shown to associate with RelA, after coimmunoprecipitation, and seemed to block its binding to DNA. It is noteworthy that p50 homodimers freely bound to DNA. These results suggest that TCDD may alter the balance between NF-kappa B/Rel heterodimers and transcriptional inhibitory p50 homodimers in DCs, leading to defects in the DCs and suppression of the immune response.


1 Current address: Laboratory of Molecular Pharmacology, Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
BloodHome page
B. P. Lawrence, M. S. Denison, H. Novak, B. A. Vorderstrasse, N. Harrer, W. Neruda, C. Reichel, and M. Woisetschlager
Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound
Blood, August 15, 2008; 112(4): 1158 - 1165.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Neff-LaFord, S. Teske, T. P. Bushnell, and B. P. Lawrence
Aryl Hydrocarbon Receptor Activation during Influenza Virus Infection Unveils a Novel Pathway of IFN-{gamma} Production by Phagocytic Cells
J. Immunol., July 1, 2007; 179(1): 247 - 255.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. P. Lawrence, A. D. Roberts, J. J. Neumiller, J. A. Cundiff, and D. L. Woodland
Aryl Hydrocarbon Receptor Activation Impairs the Priming but Not the Recall of Influenza Virus-Specific CD8+ T Cells in the Lung
J. Immunol., November 1, 2006; 177(9): 5819 - 5828.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
K. A. Mitchell and B. P. Lawrence
Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Renders Influenza Virus-Specific CD8+ T Cells Hyporesponsive to Antigen
Toxicol. Sci., July 1, 2003; 74(1): 74 - 84.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics